ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and renal diseases, including its lead asset IC 100, a humanized monoclonal antibody targeting the inflammasome. The company entered the public markets through its 2022 merger with ITHAX Acquisition Corp, a healthcare-focused SPAC that completed its IPO in 2021 under sponsor ITHAX Sponsor LLC. ZyVersa's March 2025 8-K filing reflects its ongoing SEC reporting obligations as a post-combination public company operating in the biopharma sector. Sign up for SpacDesk to access full filing histories, sponsor profiles, and deal-level analytics on ZVSA and hundreds of other SPAC-linked companies.